The convergence of genomics and prescription drugs is not a medical breakthrough. It is a strategic pivot in the landscape of asymmetric warfare. For years, I have warned that the digitisation of biological data creates a high-value target for hostile state actors. Now, with the rise of personalised medicine, we are handing them the blueprint for population-specific bioweapons.

Let us examine the threat vectors. Every genome sequenced, every prescription tailored to a specific genetic profile is a piece of intelligence. A hostile actor with access to a national biobank could, in theory, identify polymorphisms that confer susceptibility to a pathogen or toxin. They could then design a weapon that targets a particular ethnic group, a specific region, or even a family. This is not science fiction. This is the logical endpoint of weaponised genomics.

Consider the logistics. The UK's 100,000 Genomes Project, the US All of Us programme these are treasure troves. The security around these databases is woefully inadequate. We treat genetic data like medical records, when they are in fact strategic assets. A breach is not a matter of if, but when. We saw a precursor in the 2018 MyHeritage breach, where 92 million accounts were compromised. That was a dry run.

The intelligence failure here is staggering. We are allowing private companies to accumulate genetic data with minimal oversight. The regulatory framework is a joke. GDPR is toothless when a nation-state decides to hunt for vulnerabilities. And the pharmaceutical industry is complicit. They are racing to develop targeted therapies without considering the offensive applications. Every clinical trial is a reconnaissance mission for a potential adversary.

There is also the supply chain threat. Customised drugs require customised manufacturing. That means small batches, specific ingredients, and often a single point of failure. A state actor could target a production facility with a cyberattack, scrambling the genetic sequences or contaminating the raw materials. The result would not just be a supply shortage. It would be a population-scale poisoning event.

We need a strategic reassessment. First, classify all genomic databases as critical national infrastructure. Second, impose export controls on sequencing technology. Third, stop treating DNA as personal property. It is a national security asset. The American and British governments must lead a coalition to establish a defensive genomic framework. We need to harden our targets, identify the vulnerabilities in our own population, and prepare for the inevitable attack.

Personalised medicine promises to revolutionise healthcare. But every revolution has a counter-revolution. The same technology that cures cancer can also target a people. We are not ready. The threat vectors are multiplying, and we are sleepwalking into a biological Pearl Harbor.